Venetoclax
Blasts 10 Percent or More of Peripheral Blood White Cells
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
684 Active assets in the Blasts 10 Percent or More of Peripheral Blood White Cells cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gemtuzumab M.D. Anderson Cancer Center | Phase 4 | A |
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BBB |
AMSACRINE University Hospital, Toulouse | Phase 4 | BBB |
Posaconazole AstraZeneca | Phase 4 | BBB |
(+)-VINCRISTINE Janssen Research & Development, LLC | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Venetoclax is also rated in:
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →